Replimune

Replimune staged a single-session rally during regular trading, surging 5.17% to $11.800 as of ET 09:58, driven by the FDA's acceptance of its resubmitted Biologics License Application for lead candidate RP1 in melanoma, alongside compelling ASCO data showing RP1 plus nivolumab achieved a median overall survival of 32.9 months in anti-PD-1-failed melanoma patients. The stock climbed steadily from a pre-market low of $11.086. The company's FY2026 net loss widened to $313.9 million with R&D expenses rising to $221.2 million, but the cash runway extending into 2027 alleviated near-term funding concerns. The current price sits well above the MA60 ($6.166) and MA20 ($10.169), with a YTD gain of 32.58%, though it remains 10.88% below the 52-week high of $13.24, and several analysts have raised their 12-month price target from $7.67 to $8.17, implying roughly 30% downside.